CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,431 enrolled
Drug / intervention
Empagliflozindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05350202
NCT05350202N/ACompleted

Empagliflozin Functional Capacity - Non-Interventional Study

Boehringer Ingelheim·observational·Posted Apr 28, 2022·Updated Aug 26, 2025

In Brief

An observational study evaluating Empagliflozin for Heart Failure. Completed, enrolled 3,431 participants across 350 sites in 6 countries.

Detailed Summary

This is a multinational non-interventional study based on newly collected data to assess demographics, disease, and treatment pattern of patients with chronic Heart Failure (HF) in a two-cohort design: one cohort will receive first prescription of empagliflozin as routine therapy for HF, the other cohort will receive HF therapy with drugs with another mechanism of action. Treatment of HF according to routine practice is determined by the physician independent of the participation of the patient in this non-interventional study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesBulgaria, Czechia, Hungary, Poland, Romania, Switzerland
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 28, 2022
Enrollment StartDec 18, 2022
Primary CompletionJul 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.2 years ago

Interventions

Empagliflozindrug

Empagliflozin was administered according to the approved product information.